Intratrial Exposure to Vitamin D and New-Onset Diabetes Among Adults With Prediabetes: A Secondary Analysis From the Vitamin D and Type 2 Diabetes (D2d) Study. Diabetes Care 2020;43:2916–2922
Abstract
This letter concerns the secondary analysis (1) of the Vitamin D and Type 2 Diabetes (D2d) study (2). The D2d study was a randomized controlled trial to determine whether vitamin D supplementation (4,000 IU per day) reduced the risk of diabetes among adults with prediabetes (2). In an intention-to-treat analysis, vitamin D nonsignificantly reduced new-onset diabetes by 12% compared with the placebo (2). A secondary analysis was subsequently performed that evaluated hazard ratios (HRs) of developing diabetes in the entire cohort stratified by different achieved levels of vitamin D (1). When adjusted for treatment assignment only (vitamin D or placebo [model 1]) and compared with the cohort of achieving the vitamin D sufficient range of 50–75 nmol/L, those in the highest two cohorts of achieved vitamin D levels of 100–124 nmol/L and $125 nmol/L had significantly decreased HRs of 0.65 and 0.41, respectively (1). The results were progressively adjusted for the following potential confounders: baseline BMI, race (model 2); sex, age (model 3); baseline physical activity (model 4); and baseline statin use (model 5). All of these adjustments lowered the HRs of model 1 of the 100–124 nmol/L and $125 nmol/L cohorts by only 0.08 and 0.06, respectively, suggesting that these potential confounders did not play a large role. Weight loss is the most important factor in delaying or preventing the development of diabetes in individuals with prediabetes (3). It seems possible that those…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.